Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus
Simon K.B. Spohn
(1)
,
C. Draulans
(2)
,
A.U. Kishan
(3)
,
Daniel E. Spratt
(4)
,
A. Ross
(5)
,
T. Maurer
(6)
,
Derya Tilki
(6)
,
Alejandro Berlin
(7)
,
Pierre Blanchard
(8, 9, 10)
,
S. Collins
,
P. Bronsert
(1)
,
Ronald C. Chen
(11)
,
A.D. Pra
(12)
,
G. de Meerleer
(2)
,
Thomas Eade
(13)
,
K. Haustermans
(2)
,
T. Hölscher
(14)
,
S. Höcht
,
Pirus Ghadjar
(15)
,
E. Davicioni
(16)
,
M. Heck
(17)
,
Linda G.W. Kerkmeijer
(18)
,
Simon Kirste
(1)
,
N. Tselis
(19)
,
Phuoc T. Tran
(20)
,
M. Pinkawa
(21)
,
P. Pommier
(22)
,
Constantinos D. Deltas
(23)
,
N.-S. Schmidt-Hegemann
(24)
,
T. Wiegel
(25)
,
Thomas Zilli
(26)
,
A.C. Tree
(27)
,
X. Qiu
(28)
,
V. Murthy
(29)
,
Jonathan I. Epstein
(30)
,
Christian Graztke
(1)
,
Xin Gao
(31)
,
A.L. Grosu
(1)
,
Sophia C. Kamran
(32)
,
C. Zamboglou
(1, 33)
1
University of Freiburg [Freiburg]
2 KU Leuven - Catholic University of Leuven = Katholieke Universiteit Leuven
3 UCLA - University of California [Los Angeles]
4 Case Western Reserve University [Cleveland]
5 Feinberg School of Medicine
6 University Hospital Hamburg-Eppendorf
7 University of Toronto
8 IGR - Institut Gustave Roussy
9 U1018 (Équipe 2) - Oncostat
10 CESP - Centre de recherche en épidémiologie et santé des populations
11 University of Kansas [Kansas City]
12 University of Miami
13 RNSH - Royal North Shore Hospital
14 TU Dresden - Technische Universität Dresden = Dresden University of Technology
15 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
16 Veracyte SAS
17 TUM - Technische Universität Munchen - Technical University Munich - Université Technique de Munich
18 Radboud University Medical Center [Nijmegen]
19 Johann Wolfgang Goethe University Hospital
20 University of Maryland [Baltimore]
21 MediClin Robert-Janker-Klinik [Bonn]
22 Centre Léon Bérard [Lyon]
23 UCY - University of Cyprus [Nicosia]
24 LMU Munich - Ludwig-Maximilians University Hospital
25 Universitätsklinikum Ulm - University Hospital of Ulm
26 HUG - Geneva University Hospital
27 The institute of cancer research [London]
28 NJU - Nanjing University
29 Tata Memorial Centre
30 Johns Hopkins University School of Medicine [Baltimore]
31 Massachusetts General Hospital [Boston]
32 HMS - Harvard Medical School [Boston]
33 European University of Cyprus
2 KU Leuven - Catholic University of Leuven = Katholieke Universiteit Leuven
3 UCLA - University of California [Los Angeles]
4 Case Western Reserve University [Cleveland]
5 Feinberg School of Medicine
6 University Hospital Hamburg-Eppendorf
7 University of Toronto
8 IGR - Institut Gustave Roussy
9 U1018 (Équipe 2) - Oncostat
10 CESP - Centre de recherche en épidémiologie et santé des populations
11 University of Kansas [Kansas City]
12 University of Miami
13 RNSH - Royal North Shore Hospital
14 TU Dresden - Technische Universität Dresden = Dresden University of Technology
15 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
16 Veracyte SAS
17 TUM - Technische Universität Munchen - Technical University Munich - Université Technique de Munich
18 Radboud University Medical Center [Nijmegen]
19 Johann Wolfgang Goethe University Hospital
20 University of Maryland [Baltimore]
21 MediClin Robert-Janker-Klinik [Bonn]
22 Centre Léon Bérard [Lyon]
23 UCY - University of Cyprus [Nicosia]
24 LMU Munich - Ludwig-Maximilians University Hospital
25 Universitätsklinikum Ulm - University Hospital of Ulm
26 HUG - Geneva University Hospital
27 The institute of cancer research [London]
28 NJU - Nanjing University
29 Tata Memorial Centre
30 Johns Hopkins University School of Medicine [Baltimore]
31 Massachusetts General Hospital [Boston]
32 HMS - Harvard Medical School [Boston]
33 European University of Cyprus
Simon K.B. Spohn
Connectez-vous pour contacter l'auteur
- Fonction : Auteur correspondant
- PersonId : 1260804
Connectez-vous pour contacter l'auteur
Daniel E. Spratt
- Fonction : Auteur
- PersonId : 1257296
- ORCID : 0000-0002-5973-4741
Alejandro Berlin
- Fonction : Auteur
- PersonId : 1260805
- ORCID : 0000-0002-1880-6905
S. Collins
- Fonction : Auteur
Thomas Eade
- Fonction : Auteur
- PersonId : 1260806
- ORCID : 0000-0003-4324-1886
S. Höcht
- Fonction : Auteur
Phuoc T. Tran
- Fonction : Auteur
- PersonId : 1260807
- ORCID : 0000-0002-0147-0376
Constantinos D. Deltas
- Fonction : Auteur
- PersonId : 1260808
- ORCID : 0000-0001-5549-9169
Thomas Zilli
- Fonction : Auteur
- PersonId : 1257302
- ORCID : 0000-0002-4784-9883
Xin Gao
- Fonction : Auteur
- PersonId : 1260809
- ORCID : 0000-0001-7038-2858
Sophia C. Kamran
- Fonction : Auteur
- PersonId : 1260810
- ORCID : 0000-0001-9283-6515
Résumé
Current risk-stratification systems for prostate cancer (PCa) do not sufficiently reflect the disease heterogeneity. Genomic classifiers (GC) enable improved risk stratification after surgery, but less data exist for patients treated with definitive radiation therapy (RT) or RT in oligo-/metastatic disease stages. To guide future perspectives of GCs for RT, we conducted (1) a systematic review on the evidence of GCs for patients treated with RT and (2) a survey of experts using the Delphi method, addressing the role of GCs in personalized treatments to identify relevant fields of future clinical and translational research. We performed a systematic review and screened ongoing clinical trials on ClinicalTrials.gov. Based on these results, a multidisciplinary international team of experts received an adapted Delphi method survey. Thirty-one and 30 experts answered round 1 and round 2, respectively. Questions with ≥75% agreement were considered relevant and included in the qualitative synthesis. Evidence for GCs as predictive biomarkers is mainly available to the postoperative RT setting. Validation of GCs as prognostic markers in the definitive RT setting is emerging. Experts used GCs in patients with PCa with extensive metastases (30%), in postoperative settings (27%), and in newly diagnosed PCa (23%). Forty-seven percent of experts do not currently use GCs in clinical practice. Expert consensus demonstrates that GCs are promising tools to improve risk-stratification in primary and oligo-/metastatic patients in addition to existing classifications. Experts were convinced that GCs might guide treatment decisions in terms of RT-field definition and intensification/deintensification in various disease stages. This work confirms the value of GCs and the promising evidence of GC utility in the setting of RT. Additional studies of GCs as prognostic biomarkers are anticipated and form the basis for future studies addressing predictive capabilities of GCs to optimize RT and systemic therapy. The expert consensus points out future directions for GC research in the management of PCa.
Domaines
Sciences du Vivant [q-bio]Format du dépôt | Fichier |
---|---|
Type de dépôt | Article dans une revue |
Titre |
en
Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus
|
Résumé |
en
Current risk-stratification systems for prostate cancer (PCa) do not sufficiently reflect the disease heterogeneity. Genomic classifiers (GC) enable improved risk stratification after surgery, but less data exist for patients treated with definitive radiation therapy (RT) or RT in oligo-/metastatic disease stages. To guide future perspectives of GCs for RT, we conducted (1) a systematic review on the evidence of GCs for patients treated with RT and (2) a survey of experts using the Delphi method, addressing the role of GCs in personalized treatments to identify relevant fields of future clinical and translational research. We performed a systematic review and screened ongoing clinical trials on ClinicalTrials.gov. Based on these results, a multidisciplinary international team of experts received an adapted Delphi method survey. Thirty-one and 30 experts answered round 1 and round 2, respectively. Questions with ≥75% agreement were considered relevant and included in the qualitative synthesis. Evidence for GCs as predictive biomarkers is mainly available to the postoperative RT setting. Validation of GCs as prognostic markers in the definitive RT setting is emerging. Experts used GCs in patients with PCa with extensive metastases (30%), in postoperative settings (27%), and in newly diagnosed PCa (23%). Forty-seven percent of experts do not currently use GCs in clinical practice. Expert consensus demonstrates that GCs are promising tools to improve risk-stratification in primary and oligo-/metastatic patients in addition to existing classifications. Experts were convinced that GCs might guide treatment decisions in terms of RT-field definition and intensification/deintensification in various disease stages. This work confirms the value of GCs and the promising evidence of GC utility in the setting of RT. Additional studies of GCs as prognostic biomarkers are anticipated and form the basis for future studies addressing predictive capabilities of GCs to optimize RT and systemic therapy. The expert consensus points out future directions for GC research in the management of PCa.
|
Auteur(s) |
Simon K.B. Spohn
1
, C. Draulans
2
, A.U. Kishan
3
, Daniel E. Spratt
4
, A. Ross
5
, T. Maurer
6
, Derya Tilki
6
, Alejandro Berlin
7
, Pierre Blanchard
8, 9, 10
, S. Collins
, P. Bronsert
1
, Ronald C. Chen
11
, A.D. Pra
12
, G. de Meerleer
2
, Thomas Eade
13
, K. Haustermans
2
, T. Hölscher
14
, S. Höcht
, Pirus Ghadjar
15
, E. Davicioni
16
, M. Heck
17
, Linda G.W. Kerkmeijer
18
, Simon Kirste
1
, N. Tselis
19
, Phuoc T. Tran
20
, M. Pinkawa
21
, P. Pommier
22
, Constantinos D. Deltas
23
, N.-S. Schmidt-Hegemann
24
, T. Wiegel
25
, Thomas Zilli
26
, A.C. Tree
27
, X. Qiu
28
, V. Murthy
29
, Jonathan I. Epstein
30
, Christian Graztke
1
, Xin Gao
31
, A.L. Grosu
1
, Sophia C. Kamran
32
, C. Zamboglou
1, 33
1
University of Freiburg [Freiburg]
( 68615 )
- Friedrichstr. 39 79098 Freiburg
- Allemagne
2
KU Leuven -
Catholic University of Leuven = Katholieke Universiteit Leuven
( 300656 )
- Oude Markt 13 - bus 5005, 3000 Leuven
- Belgique
3
UCLA -
University of California [Los Angeles]
( 72398 )
- Los Angeles, Californie 90095
- États-Unis
4
Case Western Reserve University [Cleveland]
( 365163 )
- 10900 Euclid Ave., Cleveland, Ohio 44106
- États-Unis
5
Feinberg School of Medicine
( 360635 )
- Arthur J. Rubloff Building
420 East Superior Street
Chicago, IL 60611
- États-Unis
6
University Hospital Hamburg-Eppendorf
( 136748 )
- Phoniatrics and Pedaudiology, Martinistraße 52, 20246 Hamburg
- Allemagne
7
University of Toronto
( 300722 )
- 27 King's College Circle, Toronto M5S 1A1
- Canada
8
IGR -
Institut Gustave Roussy
( 156104 )
- 114, rue Édouard-Vaillant 94805 Villejuif Cedex -France
- France
9
U1018 (Équipe 2) -
Oncostat
( 1051100 )
- Gustave Roussy.
114 rue Édouard Vaillant, 94805 Villejuif Cedex
- France
10
CESP -
Centre de recherche en épidémiologie et santé des populations
( 1051097 )
- 16 avenue Paul Vaillant Couturier 94807 Villejuif Cedex, France
- France
11
University of Kansas [Kansas City]
( 493860 )
- Kansas City, KS, USA
- États-Unis
12
University of Miami
( 325826 )
- Coral Gables, FL 33124
305-284-2211
- États-Unis
13
RNSH -
Royal North Shore Hospital
( 349561 )
- Australie
14
TU Dresden -
Technische Universität Dresden = Dresden University of Technology
( 96520 )
- TU Dresden 01062 Dresden
- Allemagne
15
Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
( 1062372 )
- Charitéplatz 1,
10117 Berlin
- Allemagne
16
Veracyte SAS
( 1148925 )
- Marseille
- France
17
TUM -
Technische Universität Munchen - Technical University Munich - Université Technique de Munich
( 132871 )
- Arcisstrasse 21, D- 80333 München
- Allemagne
18
Radboud University Medical Center [Nijmegen]
( 305057 )
- 6500 HB Nijmegen
- Pays-Bas
19
Johann Wolfgang Goethe University Hospital
( 333606 )
-
- France
20
University of Maryland [Baltimore]
( 483979 )
- Baltimore, MD 21201
- États-Unis
21
MediClin Robert-Janker-Klinik [Bonn]
( 1051563 )
- Allemagne
22
Centre Léon Bérard [Lyon]
( 20549 )
- 28, rue Laennec 69373 LYON Cedex 08
- France
23
UCY -
University of Cyprus [Nicosia]
( 71226 )
- 1 Panepistimiou Avenue, University House "Anastasios G. Leventis", P.O. Box 20537, Aglatzia
- Chypre
24
LMU Munich -
Ludwig-Maximilians University Hospital
( 336821 )
- Allemagne
25
Universitätsklinikum Ulm - University Hospital of Ulm
( 323194 )
- Ulm, Allemagne
- Allemagne
26
HUG -
Geneva University Hospital
( 300992 )
- Suisse
27
The institute of cancer research [London]
( 412235 )
- 123 Old Brompton Road
London SW7 3RP
- Royaume-Uni
28
NJU -
Nanjing University
( 305873 )
- Nanjing, Jiangsu Province
- Chine
29
Tata Memorial Centre
( 471081 )
- Dr. E, Dr Ernest Borges Rd, Parel, Mumbai, Maharashtra 400012, Inde
- Inde
30
Johns Hopkins University School of Medicine [Baltimore]
( 148207 )
- 733 North Broadway, Suite G49
Baltimore, MD 21205-2196
- États-Unis
31
Massachusetts General Hospital [Boston]
( 309442 )
- 55 Fruit Street
Boston, MA 02114
- États-Unis
32
HMS -
Harvard Medical School [Boston]
( 130467 )
- 25 Shattuck Street Boston, MA 02115
- États-Unis
33
European University of Cyprus
( 1065149 )
- Diogenis Str 6 Nicosia CY, 2404, Chypre
- Chypre
|
Langue du document |
Anglais
|
Nom de la revue |
|
Numéro |
3
|
Volume |
116
|
Page/Identifiant |
503-520
|
Date de publication |
2023
|
Audience |
Internationale
|
Vulgarisation |
Non
|
Comité de lecture |
Oui
|
Domaine(s) |
|
Financement |
|
DOI | 10.1016/j.ijrobp.2022.12.038 |
Pubmed Id | 36596346 |
Origine :
Publication financée par une institution
Licence :
Paternité - Pas d'utilisation commerciale - Pas de modification
- CC BY 4.0
Licence :
![](/build/img/licences/cc.1ab04b8f.png)
![](/build/img/licences/by.1a6bf697.png)
![](/build/img/licences/nc.10ff91f8.png)
![](/build/img/licences/nd.6a7d85ee.png)
Loading...